Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.1%. By the end of trading, Vertex Pharmaceuticals fell $1.74 (-2.1%) to $81.40 on light volume. Throughout the day, 1,594,034 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,481,400 shares. The stock ranged in price between $81.09-$84.84 after having opened the day at $81.92 as compared to the previous trading day's close of $83.14. Other companies within the Drugs industry that declined today were: Biota Pharmaceuticals ( BOTA), down 67.6%, Cardium Therapeutics ( CXM), down 12.2%, OvaScience ( OVAS), down 7.7% and ImmunoCellular Therapeutics ( IMUC), down 7.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.3 billion and is part of the health care sector. Shares are up 97.6% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

On the positive front, Progenics Pharmaceuticals ( PGNX), down 31.0%, Vanda Pharmaceuticals ( VNDA), down 25.0%, Rexahn Pharmaceuticals ( RNN), down 19.1% and Catalyst Pharmaceutical Partners ( CPRX), down 18.5% , were all gainers within the drugs industry with Novo Nordisk A/S ( NVO) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting